cyrilzakka/clinical-trials huggingface dataset:
Nutritional Status of Patients Victims of Haemorragic Accidents With Antivitamins K

Bleeding under vitamin K antagonists are a major iatrogenic causes of hospitalization, subject to a fatal outcome in more than one third of cases, mortality is particularly high in cases of serious bleeding, including intracerebral hemorrhage. If the INR measured in these patients are often away from the higher value of the target range, a significant proportion of bleeding were observed for INR between 2 and 3. The study captures the components of the nutritional status of patients on oral anticoagulants, including any micronutrient deficiencies, to determine whether nutritional status is an independent risk factor for bleeding

Be included in this study patients under anti-vitamin K supported or followed the emergency department Adults.

The inclusion visit will be conducted in the emergency department Adults Clermont-Ferrand by an emergency physician or investigator or co-investigator. The protocol will be explained to patients in detail, the information document and consent will be issued for playback, then they will be asked to sign the consent form and participation agreement.

Case-control study: patients under oral anticoagulant with severe hemorrhagic accident compared with patients without hemorrhagic accident. Cases will be matched to controls based on age, sex, and the value of the INR.

Patients will be divided into two groups:

* Group 1: cases Patient under anti-vitamin K with a serious bleeding event that required treatment in the emergency Adults. Is considered serious accident requiring the use of a reversion by PPSB (Kaskadil ®).
* Group 2: contols Patient under anti-vitamin K with no haemorrhagic manifestations admitted for another reason to Emergency Adults

Each case will be paired with two controls

Eligibility Criteria:
Inclusion Criteria:

* Patients, male or female, aged over 18, under oral anticoagulant therapy with antivitamins K.
* INR greater than 1.5, in the therapeutic range or overdose
* Patient have read, understood and signed the consent form or inclusion emergency consent of the person with confidence
* Case-control study: patients under oral anticoagulant with severe hemorrhagic accident compared with patients without hemorrhagic accident. Cases will be matched to controls based on age, sex, and the value of INR :

Case:

Patients victims of serious hemorrhagic accident on VKAs, supported emergency Adults.

Will be considered severe hemorrhagic stroke, accidents requiring the use of a reversion by PPSB (Kaskadil ®)

Control :

Patients on VKAs supported the Emergency Adults for a reason other than bleeding.

Exclusion Criteria:

* underage patients
* Patients who have not read or understood nor signed the consent form or refusal of the reference person.
* pregnant women
* Patients with a pacemaker and / or implantable defibrillator
* Patients with mechanical valve
Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain

Investigators propose to develop hyperpolarized \[13C\]-labeled pyruvate as potential imaging probes to assess two essential in vivo processes in cerebral metabolism: oxidative metabolism and synthesis of a neurotransmitter in this observational study.

Investigators will perform a pilot study to test the translational feasibility by evaluating sensitivity and repeatability of hyperpolarized \[1-13C\]pyruvate and \[2-13C\]pyruvate in healthy human subjects (n =10 each). Each subject will be imaged twice using the same hyperpolarized substrate with an interval (\<45min) between the injections to evaluate repeatability. Finally, eight subjects will be imaged with both hyperpolarized \[1-13C\]pyruvate and \[2-13C\]pyruvate for comparison.

Eligibility Criteria:
Inclusion Criteria:

* 18 through 60 years of age.
* Healthy, with no neurological abnormalities.
* Ability to understand and the willingness to sign a written informed consent.
* All races and ethnicities will be included; subjects must be able to read and speak the English language.

Exclusion Criteria:

* Metallic foreign bodies on the scalp or cranium which may interfere with MRI acquisitions
* Major debilitating neurological disease including, but not limited to, stroke, CVA, dementia and tumor that would limit compliance with study requirements
* Under influence of illicit drugs which are known to alter brain physiology/metabolism including, but not limited to cocaine, lysergic acid diethylamide (LSD), and marijuana at the time of MRI/MRSI scanning.
* Under influence of antiepileptic drugs at the time of MRI/MRSI scanning.
* Any contraindication per MRI Screening Form including
* Implants contraindicated at 3T, pacemakers
* Implantable Cardioverter Defibrillator (ICD)
* Claustrophobia
* Medically unstable including
* Heart failure
* Severe left ventricular outflow tract (LVOT) obstruction
* Unstable angina
* Pregnancy
* Lactating
Postpartum Glucose Tolerance With Levonorgesterel IUD Use in Women With Recent Gestational Diabetes

The study is being done in order to gain information on the most suitable types of birth control in women who recently had gestational diabetes, or diabetes diagnosed during pregnancy. The intrauterine device (IUD) is a highly effective form of birth control. It is inserted into the uterus and prevents pregnancy for either 5 or 10 years, depending on the type of IUD (hormone-releasing or copper). The hormone-releasing IUD works for 5 years and releases a hormone called a progestin into the uterus. The copper IUD contains no hormones and works for 10 years. The IUD is an excellent form of birth control postpartum, but it is unknown if the hormone-releasing IUD will affect blood sugars and increase a woman's risk of becoming diabetic when she's not pregnant. The hypothesis is that the hormone-containing IUD will NOT increase blood sugars, so women who use the hormone-containing IUD will have similar blood sugars to those who use the copper IUD or have had their tubes tied (no hormones).


Eligibility Criteria:
Inclusion Criteria:

1. Age 18-45 years at the time of enrollment
2. Single gestation in the current pregnancy
3. GDM in the current pregnancy, diagnosed by 2- or 3-hour oral glucose tolerance test (OGTT) performed at 24-32 weeks gestation
4. Desires intrauterine contraception or tubal ligation postpartum
5. Willing and able to read and sign an informed consent form in English
6. Willing to comply with the study protocol

Exclusion Criteria:

1. History of pre-gestational DM, type 1 or 2
2. Pregnancy conceived with assisted reproductive technologies
3. Positive for human immunodeficiency virus (HIV) infection
4. Desires repeat pregnancy within the first 12 months following delivery
Investigating Accelerated Learning and Memory in Healthy Subjects Using a Face Name Memory Task

The purpose of this study is to investigate whether we can accelerate learning and improve associative memory performance in healthy subjects by applying transcranial Direct Current Stimulation (tDCS) during a Face Name memory task.

Associative memory refers to remembering the association between two items, such as a face and a name or a word in English and the same word in another language. It is not only important for learning, but it is also one of the first aspects of memory performance that is impacted by aging and by Alzheimer׳s disease. For decades, neuroscientists have investigated associative learning and memory and ways to accelerate and enhance associative learning and memory.

Transcranial Direct Current stimulation (tDCS) is a non-invasive and painless electrical stimulation technique that has demonstrated to accelerate learning and improve memory in some studies. To investigate whether we can accelerate learning and improve associative memory using tDCS, we will compare the performance in a Face Name Associate memory task from 2 groups. The first group will get active tDCS during the study phase of the Face Name Memory task, whereas the second group will get sham tDCS during the study phase of the task.

Eligibility Criteria:
Inclusion Criteria:

* Age: 18-35 years
* Native English Speaker

Exclusion Criteria:

* History of severe head injuries, epileptic insults, or heart disease.
* Severe psychiatric disorders and severe untreated medical problems.
* Contraindications for tDCS (pregnant women, implanted devices)
Identification, Electro-mechanical Characterisation and Ablation of Driver Regions in Persistent Atrial Fibrillation

Atrial fibrillation (AF) is the most common sustained heart rhythm abnormality. Its incidence is increasing partly due to the aging population and it has been referred to as a growing epidemic. AF results in irregular contractions of the heart causing unpleasant symptoms of palpitations and increasing the risk of stroke, heart failure and death. Percutaneous catheter ablation is a safe treatment option in symptomatic patients with AF. The success rate of these procedures have improved with time due to our better understanding of AF, development of new techniques and technology, and greater physician experience. However, the success rate of these procedures still only remains around 70%. This is secondary to our limited ability to find the areas that drive AF.

STAR mapping is a novel mapping system that has been developed with a view of better identifying the sites that drive AF through taking into account the mechanisms of AF we have so far demonstrated. To validate this mapping system we aim to use it in patients with atrial tachycardia (AT), which is a heart rhythm abnormality of which the mechanism can be readily identified with the existing mapping systems used in clinical practice. We will demonstrate that the STAR mapping algorithm can effectively map AT.

AT is a heart rhythm that currently can be effectively mapped and ablated using existing mapping systems. The mechanism of this heart rhythm is well understood.

Patients that are scheduled for a catheter ablation for AT by their Electrophysiologist will be enrolled into the study. The patient will have the procedure under local anaesthetics/sedation or general anaesthetic depending on their clinical need.

During the procedure tubes will be passed into the left upper chamber of the heart through the groin. Through these tubes catheters will be used to create a geometry of the heart chamber. Following this, in half of the patients a basket catheter with 64 electrodes will be positioned in the upper chamber whilst conventional catheters will be used in the other half of the patients. The aim of this is to demonstrate that the STAR mapping can be used with multiple mapping catheters. Signals i.e. electrograms will then be collected and used with the STAR mapping algorithm. The AT will then be effectively mapped and ablated with a conventional mapping system. The STAR mapping will then be used for post processing after the case to map the AT and will be compared to the maps generated by the conventional system. This will enable validation of the STAR mapping system.

Eligibility Criteria:
Inclusion Criteria:

1. Patients able to provide informed consent
2. Patients with AT (whether de novo or occurring post AF ablation)

Exclusion Criteria:

1. Unwillingness to sign consent
2. Age \<18 years old
3. Contraindications for catheter ablation procedure
Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis

OBJECTIVES: I. Compare the resting energy expenditure using respiratory calorimetry in infants and children with moderate to severe cystic fibrosis versus age matched healthy controls.

II. Determine the total energy expenditure and energy spent on physical activity using the doubly labeled water method in these patient populations.

PROTOCOL OUTLINE: Patients and healthy controls receive an oral dose of doubly labeled water following initial urine collection on day 1. Patients undergo additional urine collection at 4-6 hours following doubly labeled water consumption and then daily for 7 days.

Additionally, at the beginning of the study, patients and healthy controls undergo respiratory calorimetry over approximately 45 minutes at rest, starting approximately 2-3 hours after the last meal consumption and last use of aerosol bronchodilators (if required).

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

* Diagnosis of cystic fibrosis (CF) by two positive sweat tests No exacerbations of present condition within past 2 months FEV1 less than 50% of predicted No other uncorrected lung disease No requirement for supplemental oxygen

OR

* Healthy (control group) Age matched to CF patients No preexisting lung disease Clinically well No hospitalizations within past 6 months

--Prior/Concurrent Therapy--

* Concurrent pancreatic enzyme supplementation for CF required Clinically stable on current medications (CF patients)

--Patient Characteristics--

* Age: Birth to 12 months 6 to 10 years
* Cardiovascular: No major cardiovascular problems (CF patients) No preexisting heart disease (control group)
* Pulmonary: See Disease Characteristics
* Other: No chromosomal abnormalities (CF patients) No acute infection (CF patients) No diabetes mellitus (both groups)
The Effect of Music Listening on Nursing Students

The purpose of this study is to explore the effect of sedative and stimulative music listening on physiological responses among nursing students.


Eligibility Criteria:
Inclusion criteria:

* a senior, junior, or second-semester sophomore in the traditional undergraduate Bachelor of Science in Nursing (BSN) program
* a student in the accelerated BSN program

Exclusion criteria:

•self-reported hearing impairments.
The Clinical Application of EIT in Clinically Ill Patients: a Cross-sectional Study

The application of electrical impedance tomography (EIT) in intensive care is increasing. It can provide additional information on individual respiratory physiology of patients, enabling clinicians or respiratory therapists to monitor patients' respiratory responses to different ventilator settings, respiratory treatment methods or clinical evolution, and thus achieve more personalized mechanical ventilation methods. Although this technology provides a large amount of valuable information, there is still uncertainty about how to use it and interpret the results in critically ill patients. Therefore, the evidence that EIT-guided ventilation strategies can improve prognosis is still in its infancy. Through this survey, the investigators aim to understand the current experiences and guiding roles of EIT in clinical practice. The secondary objective is to learn about the current challenges of EIT in clinical and practical settings, as well as the factors that promote or hinder the implementation of EIT monitoring technology.


Eligibility Criteria:
Inclusion Criteria:

* occupation is "respiratory therapist or part-time respiratory therapy doctor/nurse";
* work city or area belongs to China;
* to complete electronic questionnaires to fill out and submit.

Exclusion Criteria:

* work city or area not belongs to China;
* The questionnaire is not completed or quit midway;
* Other invalid questionnaires.
Dose-ranging Study of Ramosetron for the Prevention of Nausea and Vomiting After Gynecologic Laparoscopic Surgery

Many patients receiving opioid based analgesia after gynecologic laparoscopic surgery experience postoperative nausea and vomiting (PONV) despite prophylaxis and treatment with HT3 receptor antagonists. Although a high dose of ramosetron can cause adverse effects such as headache or dizziness, the minimal effective dose of ramosetron in a high-risk patients is unknown. The aim of this study is to determine the effective dose of ramosetron for prophylaxis of PONV in a high-risk patients receiving intravenous opioid-based patient-controlled analgesia after gynecological laparoscopic surgery.


Eligibility Criteria:
Inclusion Criteria:

* patient between 20 and 70 of age with ASA physical status Ⅰ-Ⅱ
* patient scheduled for elective gynecological laparoscopic surgery.

Exclusion Criteria:

* hepatorenal disease
* BMI \> 35 kg/m2
* allergy to ramosetron
* gastrointestinal disease
* vomiting within 24h
* administration of antiemetics or opioids within 24h
* QT prolongation (QTc \> 440ms)
* pregnant
* problem with communication
Evaluation of an Airway Clearance System

The aim of this study is to assess the effectiveness of an Airway Clearance System.

The study will compare the effectiveness of The Monarch™ System and The Vest® Airway Clearance System. All subjects will receive treatment with both systems and endpoints will be compared.

Eligibility Criteria:
Inclusion Criteria:

* Documented diagnosis of Cystic Fibrosis (CF) (by sweat test and/or genetics)
* Age ≥ 15 years
* Ability to expectorate sputum daily - determined by treating physician
* Patient must be on a stable regimen of CF medication for 4 weeks prior to Visit 1
* Patient who requires regular home airway clearance therapy

Exclusion Criteria:

* Forced Expiratory Volume in 1 Second (FEV1) \< 30 % predicted or \> 90 % predicted
* Anticipated requirement for hospitalization within the next three weeks
* History of pneumothorax within the past 6 months prior Visit 1
* History of haemoptysis requiring embolization within the past 12 months prior to Visit 1
* Inability to perform Monarch™ and/or Vest® System therapy as directed
* Unable or unwilling to complete study visits or provide follow-up data as required per the study protocol
* Has taken Intravenous (IV) antibiotics within the past 4 weeks prior to Visit 1
* Has ongoing exacerbation or Allergic bronchopulmonary aspergillosis (ABPA)
* Pregnant or lactating female
* Has a pacemaker or implantable cardioverter defribillator (ICD)
Neoadjuvant SBRT in Localized Advanced HNSCC

The response rate of HNSCC to immune checkpoint blockade was not satisfied. Improving the mPR rate of neoadjuvant immunotherapy through the combination with other treatment methods is an important way to further improve the prognosis of such patients. This study aims to explore the efficacy and safety of PD-1 monoclonal antibody with neoadjvant SBRT and chemotherapy. The triple mode not only can Increase the effectiveness of neoadjuvant therapy，meanwhile，the in situ tumor vaccine inoculation effect generated by enhancing the release of specific antigens after tumor radiotherapy with PD-1 monoclonal antibody achieves a sustained anti-tumor immune effect throughout the body， reducing postoperative adjuvant radiotherapy and chemotherapy. The triple mode has important exploratory value in achieving high quality and long-term survival for patients, and may provides a more efficient mode for locally advanced HNSCC.

locally advanced HNSCC patients would receive PD-1 antibody and chemotherapy with or without SBRT covering GTV of primary disease and metastatic nodes , followed by surgery. pathological response was measured .Neoadjuvant PD-1 antibody and chemotherapy with certuxmab was also tested

Eligibility Criteria:
Inclusion Criteria:

1. Pathologically confirmed initially resectable Localized advanced head and neck squamous cell carcinoma，and plan for surgical resection.
2. Immunohistochemical confirmed the HPV status through P16 immunostaining.
3. Male or female, Between the aged from 18 to 70 years,
4. Able to provide informed consent, comply with agreements, and sign research specific consent documents.
5. ZPS is less than 2.
6. Adequate bone marrow, liver and kidney, heart , lung and other physiological function determined by Researchers, able to tolerate neoadjuvant anti-PD-1, anti-EGFR, and radiation therapy.
7. Subjects are willing and able to comply with visits, treatment regimens, laboratory tests, and other requirements of the study as spe.

Exclusion Criteria:

1. Any clinical illness, such as hemorrhage, active infection, or mental illness, that can hinder safe participation or adherence of research procedures.
2. Patients who cannot accept radiotherapy in standard treatment.
3. Long term maintenance of oral steroids (≥ 20mg prednisone equivalent per day) is required, excluding patients with inhaled, local, or non absorbable steroids.
4. Autoimmune diseases, including but not limited to inflammatory bowel disease, rheumatoid arthritis, autoimmune hepatitis, systemic sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathy (such as Guillain Barre syndrome), etc.
GTP Regimen in the Treatment of Refractory/Recurrent HLH

The goal of this clinical trial is to learn about efficacy and safety of GTP regimen in refractory/recurrent hemophagocytic lymphohistiocytosis. The main questions it aims to answer are:

* Overall remission rate of GTP regimen in R/R HLH
* Adverse effect of GTP regimen Participants will be treated with GTP regimen

Refractory/recurrent hemophagocytic lymphohistiocytosis will be treated with emapalumab combined with teniposide and methylprednisolone. Observed the overall response rate and side effects.

Eligibility Criteria:
Inclusion Criteria:

1. Male and female patients ≥1 month of age with HLH
2. Definitive diagnosis of HLH: meets the molecular diagnosis of pHLH or has a family history of HLH, or meets at least 5 of the 8 diagnostic criteria of HLH-2004.
3. The investigators assessed the presence of refractory/recurrent HLH disease. Patients must meet one of the following criteria assessed by the investigator:

   * Previous conventional HLH treatment did not respond.
   * The patients were not satisfied with the efficacy of conventional HLH treatment or their condition worsened.
   * HLH reactivation occurs. Reactivation is defined as: worsening of two or more HLH clinical and laboratory criteria (after initial remission).
4. According to the researchers, the expected survival was more than 2 weeks.
5. The informed consent is signed by the patient or his legal guardian (patients under 18 years), or by the patient's legally authorized representative.
6. Women who are fertile are willing to use a highly effective contraceptive method from the start of the study until 6 months after the end of the last course of treatment.

Exclusion Criteria:

1. There is active mycobacterium, histoplasma capsulatus, Salmonella, or leishmania infection.
2. There is uncontrolled active gastrointestinal bleeding.
3. The investigator believes that there are any serious comorbidities or any other conditions that make the patient unsuitable for treatment.
4. A history of hypersensitivity or hypersensitivity to any component of the drug in the study protocol, such as polysorbate.
5. Had received the BCG vaccine within 12 weeks prior to screening.
6. Have received live or attenuated vaccine (except BCG) within 4 weeks prior to screening.
7. Pregnancy patients.
8. Within 4 weeks prior to enrollment in this study, another concurrent clinical intervention study was enrolled.
9. There is any condition or circumstance that the investigator believes may cause the patient to be unable to complete the study or to comply with study procedures or requirements.